Join Catalent’s Yuichi Kamiya, Regional Sales Director, Asia, at BIOPLUS-INTERPHEX KOREA 2026. 📍 COEX Seoul, Conference Room 317 📅 Friday, October 30 🕚 11:10–11:40 a.m. Book a meeting: ow.ly/r0nI51014Hr #BIOPLUSINTERPHEXKOREA #BIX2026 #DrugDelivery #OralDrugDelivery

Planning a study across China and Asia-Pacific? Meet our clinical supply team at the #ChinaTrials 18 to explore how our global capabilities can support your studies. Find us at Booth 5! Book a meeting with us: catalent.com/events/china-tr… #ClinicalDevelopment #ClinicalSupply

That’s a wrap on AusBiotech 2026! Thank you to everyone who connected with the Catalent team and shared insights on the innovations, challenges & opportunities shaping the future of biotechnology. #AusBiotech2026 #Biotechnology #Biopharma #DrugDevelopment #PharmaInnovation

Now available on-demand, this webinar explores how developers can proactively adapt to global regulatory expectations and build a stronger foundation for approval and patient access. Watch here: ow.ly/Z9Iq5100rmx #CellTherapy #AdvancedTherapies #Biologics

Catalent is heading to the 4th Annual CHARM Cell & Gene Therapy Symposium in Washington. Don’t miss John Tomtishen, Global Head Cell Therapy at Catalent, as he presents on October 28! Book a meeting with our experts: ow.ly/83Bs5100rhX #CellAndGeneTherapy #CHARM2026

In our executive summary, we explore best practices for navigating regulatory requirements, reducing supply risk and strengthening comparator sourcing strategies through integrated models and emerging technologies. Read now: ow.ly/zjP151001en #ClinicalSupply #Supplychain

With AAV continuing to play a critical role in gene therapy, Catalent’s on-demand webinar explores strategies for navigating manufacturing complexity and building scalable, future-ready AAV programs. Watch on-demand: ow.ly/MX1B50ZZOcX #AAV #GeneTherapy #CGT

This Disability Employment Awareness Month, we're recognizing the experiences and perspectives that help create a more inclusive workplace at Catalent. Read their reflections in this article. linkedin.com/pulse/disabilit… #DisabilityEmploymentAwarenessMonth #DEAM #Inclusion #Belonging

Join Catalent for “From Molecule to Milestone: Building and Funding the Path to the Clinic”. From early development toward clinical readiness. Register today: ow.ly/XzRG50ZZkxc #DrugDevelopment #EarlyPhaseDevelopment #BiotechFunding #ClinicalDevelopment #PharmaInnovation

Attending ChinaTrials 18? Come find us at Booth #5 in Shanghai, October 28–30. We’d love to hear what you’re working on and see if our comprehensive clinical supply services that can help support your studies. Book a 1:1 with us: ow.ly/pJem50ZZifA #ClinicalTrials

Meet Catalent at #BioplusInterphexKorea! From drug development & clinical supply to commercial capabilities, our team is here to support your product’s journey from early discovery through market launch. Book a meeting with us: ow.ly/F3gM50ZYXvH #CDMO #DrugDevelopment

Catalent is heading to #AAPS2026! Visit us at Booth #1811 to explore how our scientific expertise can help tackle complex challenges across formulation, drug delivery, scale-up, and commercialization. Connect with the team: ow.ly/5icx50ZYY6r #PharmSci360 #DrugDelivery

Attending the 2026 AusBiotech International Conference? Come meet the APAC team to learn about our flexible, comprehensive clinical supply services and how we can help support your studies. Book a meeting with us: ow.ly/2WTS50ZYX0N #ClinicalTrials #ClinicalSupply

The insights from #GCSG2026 don’t have to end in Rome. Explore how a more strategic approach to QP oversight can help keep clinical trials on track in our executive summary. Download now: ow.ly/6IUH50ZYQSP #ClinicalTrials #ClinicalSupply #ClinicalSupply

Our scientists investigated scalable drum-filling of freeze-dried antibody powders for intranasal delivery, achieving consistent low-dose filling while maintaining nasal deposition and stability. Read the article: ow.ly/5C8J50ZYmeR #RespiratoryHealth #IntranasalDelivery

Explore how a phase-appropriate strategy resolves DAR distribution, linker stability, and aggregation risk early enough to guide development from discovery through commercialization. Download the article: ow.ly/AtA950ZYmv0

In a recent @biospace article, Catalent’s Laura Daley, shares her insights on how CDMOs are evolving to support increasingly sophisticated modalities, from precise expression balancing & deeper characterization to flexible downstream strategies. Read now: ow.ly/k3IO50ZXVgi

Innovation was on full display at the recent 2026 #Endpoints11 Awards as biotechnology's rising stars were recognized for their vision, scientific excellence and commitment to advancing patient outcomes. Access the recording here: ow.ly/zKw250ZXZL8 #BiotechInnovation

Catalent's defined, U.S.-based program advances eligible bispecifics, multispecifics, and other complex molecules from gene sequence to GMP drug substance in 10 months. See whether your molecule is eligible: ow.ly/5aPc50ZXGWq #ComplexProteins #BispecificAntibodies

One week to go: Join Catalent’s Kavita Sapru to see how Tessie Nanoneedle technology compares with ELISA, ddPCR and AUC for rAAV yield characterisation, genome integrity assessment and process optimisation. Sign up now: ow.ly/85i950ZXuWk #GeneTherapy #AAV